Meta-analysis of clinical efficacy and bleeding risk with intravenous glycoprotein IIb/IIIa antagonists for percutaneous coronary intervention.
about
Gender based differences in drug eluting stent implantation - data from the German ALKK registry suggest underuse of DES in elderly women.Glycoprotein IIb/IIIa inhibitor associated severe thrombocytopenia in patients with coronary artery disease: Clinical course and outcomes.Severe thrombocytopenia and alveolar hemorrhage represent two types of bleeding tendency during tirofiban treatment: case report and literature review.Thromboembolic events secondary to tirofiban-induced thrombocytopenia being treated with thrombopoietin: A case reportEfficacy and safety of eptifibatide versus tirofiban in acute coronary syndrome patients: A systematic review and meta-analysis.Antithrombotic strategies in patients undergoing percutaneous coronary intervention for acute coronary syndrome.Peri-procedural myocardial injury during percutaneous coronary intervention: an important target for cardioprotection.Bleeding complications associated with glycoprotein IIb/IIIa inhibitors in patients 80 years of age and older undergoing percutaneous coronary interventionIntegrin targeted therapeutics.A multistudy analysis investigating systematic differences in cardiovascular trial results between Europe and Asia.How Safe is Eptifibatide during Urgent Carotid Artery Stenting?Glycoprotein IIb/IIIa receptor inhibitors in 2008: do they still have a role?Balancing the benefits and risks of antiplatelet agents in patients with non-ST-segment elevated acute coronary syndromes and undergoing percutaneous coronary intervention.Efficacy and safety of bivalirudin in patients receiving clopidogrel therapy after diagnostic angiography for percutaneous coronary intervention in acute coronary syndromes.Targeted delivery of thrombolytic agents: role of integrin receptorsAntiplatelet drugs
P2860
Q30313391-A7DF99F9-6258-4CF8-AE9F-76118C5F72AEQ33397185-6C608239-7C78-4003-B62A-685D40C3D169Q33402176-AB61CC9C-95EA-43A1-8CE1-6C314941142BQ33434082-6BB65E02-FD58-4E6D-99DE-C553C72C2E78Q33441432-074DC420-F3E5-4F52-9518-D097F6394202Q34129340-C08B78A7-9F6B-4475-A462-62C59C3D1280Q34147112-BD5790A8-2C41-484E-A032-0991D48CCF98Q34194271-A76EA449-65B4-4A5E-92BC-BA1FE9C17764Q34912684-242628FF-5148-45DD-9831-019854E7DEB1Q35495534-79181DD2-6087-4A66-AC49-595C06BD2EFBQ36602197-1E43B494-E25B-4A12-BDC2-AFF05990E494Q37126729-6EBDF699-50D7-400E-A8A5-F5475FFFF4A2Q37683552-E08BC615-A289-4E4B-8355-CBC77CC3A68CQ42873139-3EF49C13-404D-4521-B1F4-9F74DC49A2EFQ56897486-0DF34537-5E6D-40BE-A901-5EE0CA225958Q58481433-84C362D0-4C46-493C-8569-6E813B7FC6A6
P2860
Meta-analysis of clinical efficacy and bleeding risk with intravenous glycoprotein IIb/IIIa antagonists for percutaneous coronary intervention.
description
2007 nî lūn-bûn
@nan
2007 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Meta-analysis of clinical effi ...... taneous coronary intervention.
@ast
Meta-analysis of clinical effi ...... taneous coronary intervention.
@en
type
label
Meta-analysis of clinical effi ...... taneous coronary intervention.
@ast
Meta-analysis of clinical effi ...... taneous coronary intervention.
@en
prefLabel
Meta-analysis of clinical effi ...... taneous coronary intervention.
@ast
Meta-analysis of clinical effi ...... taneous coronary intervention.
@en
P2093
P2860
P1476
Meta-analysis of clinical effi ...... taneous coronary intervention.
@en
P2093
Janet Martin
Marino Labinaz
Shaila Mensinkai
Srabani Banerjee
Stella Chen
P2860
P304
P356
10.1016/S0828-282X(07)70858-9
P577
2007-10-01T00:00:00Z